Cost-effectiveness of first-line nivolumab plus ipilimumab versus platinum plus pemetrexed chemotherapy (with and without bevacizumab) in unresectable malignant pleural mesothelioma in Switzerland
Research Project | 13.05.2022 - 31.01.2023
|
13.05.2022
- 31.01.2023
Funding
Cost-effectiveness of first-line nivolumab plus ipilimumab versus platinum plus pemetrexed chemotherapy (with and without bevacizumab) in unresectable malignant pleural mesothelioma in Switzerland
Industriegelder, Sonstige Forschungskooperationen (GrantsTool), 05.2022-01.2023 (9)
PI : Barbier, Michaela.
Members (2)
Michaela Barbier
Principal Investigator
